Catalyst Wire Dossier Catalyst Wire Dossier

CAR.70-engineered IL15-transduced cord blood-derived NK cells with TGFBR2 knockout

· M.D. Anderson Cancer Center
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for CAR.70-engineered IL15-transduced cord blood-derived NK cells with TGFBR2 knockout, covering 2026-03-11 to 2026-03-27. Get the full timeline:

Most recent: Clinical Trial Update: Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies [Phase 1]

See pricing